<SUBMISSION>
<SECARCHIVE-DATETIME>		20230422-182722	 ⇐ Metadata from SEC Info (ET)
<SECWEBSITE-DATETIME>		20230421-070725	 ⇐ Metadata from SEC Info (ET)
<ACCEPTANCE-DATETIME>		20230421-070657	 ⇐ Filing accepted by SEC (ET)
<ACCESSION-NUMBER>		0001193125-23-109216
<TYPE>				ARS
<PUBLIC-DOCUMENT-COUNT>		1
<PERIOD>			20221231
<FILING-DATE>			20230421
<DATE-OF-FILING-DATE-CHANGE>	20230421
<EFFECTIVENESS-DATE>		20230421

<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>		Syros Pharmaceuticals, Inc.
<CIK>				0001556263
<ASSIGNED-SIC>			2834
<IRS-NUMBER>			453772460  ⇒ 45-3772460 or 453-77-2460
<STATE-OF-INCORPORATION>	DE
<FISCAL-YEAR-END>		1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>			ARS
<ACT>				34
<FILE-NUMBER>			001-37813
<FILM-NUMBER>			23834499
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>			35 CAMBRIDGE PARK DRIVE
<CITY>				CAMBRIDGE
<STATE>				MA
<ZIP>				02140
<PHONE>				617-744-1340
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>			35 CAMBRIDGE PARK DRIVE
<CITY>				CAMBRIDGE
<STATE>				MA
<ZIP>				02140
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>		LS22, Inc.
<DATE-CHANGED>			20120815
</FORMER-COMPANY>
</FILER>

<DOCUMENT>
<TYPE>		ARS
<SEQUENCE>	1
<FILENAME>	d501812dars.pdf
<DESCRIPTION>	ARS
<TEXT>
<PDF>
       Show <PDF>: 18,572 lines (Unix-to-Unix encoding) - 1.1M bytes  
</TEXT>
</DOCUMENT>

</SUBMISSION>